Q&A With Dr. James Salz, LA Based Lasik Surgeon

Haute MD caught up with Dr. James Salz, exclusive member of The Haute MD Network, as he shares his insight to being one of the top Lasik surgeons.

  • What inspired you to become a Lasik surgeon?
I was doing research at USC in another form of Refractive surgery, Radial Keratotomy and laser vision correction replaced this as it was safer and more accurate. We had the 3rd Visx Excimer Laser in the U. S. for the original FDA studies to approve the lasers for vision correction
  • What is currently the hottest technique you are offering patients?
It is still “All Laser LASIK” using a laser to both create the LASIK flap rather than a blade and then the excimer laser to reshape the cornea and correct the vision no matter whether the patient is nearsighted, farsighted. or has astigmatism.
  • What is your favorite and/or most rewarding part of the job?
The amazing accuracy of these procedures to remove often less than the thickness of a human hair from the cornea which usually allows the patient to have near perfect vision the next day!

  • Blackberry or iphone?
Neither I love my Samsung Epic, which is an Android based phone through Sprint. Never liked ATT as a provider because of poor coverage and dropped calls.

  • What differentiates you from other Lasik surgeons in Los Angeles?
Our group at Cedars Sinai Medical center was the first in Los Angeles to correct vision as part of the original FDA studies of PRK. I have been involved in over 10 FDA studies of vision correction which is unique.
  • What are the latest trends in Lasik/vision medicine?
The incredible advances made possible by computers and lasers which allow us not only to improve vision in patients wearing glasses but to make cataract surgery safer and more accurate. Othe specialties are reaping the same benefits through this amazing technology.
Be sure to check out  Dr. James Salz, and the other exclusive medical members on The Haute MD Network,
Like Haute Living Los Angeles? Join our Facebook page or follow us on Twitter @HauteLivingLA. Want Haute Living Los Angeles delivered to your inbox once a week? Sign up for our newsletter.

Dr. James J. Salz, M.D, has over 27 years of experience in corneal refractive surgery and has been honored with the Barraquer Award and a Lifetime Achievement award by the International Society of Refractive Surgery of the American Academy of Ophthalmology. These are the top international honors that are awarded to eye surgeons for their contributions to the field of refractive surgery. Dr. Salz has been and still is one of the principal investigators for the FDA trials involving the use of lasers to successfully and safely correct most vision problems. As a leading spokesperson for the American Academy of Ophthalmology, Dr. Salz has appeared on the Today Show, CNN, PBS, TV news programs and has been quoted extensively in major ophthalmology publications and other national magazines (such as Newsweek and Life) in the USA and abroad. Because of his conservative philosophy to refractive surgery, his opinion is routinely sought by other surgeons for patients in their own practices. He has edited numerous books and ophthalmology publications, and has published over 75 scientific articles on the subjects of refractive and cataract surgery. He has served as a volunteer surgeon and lecturer on Project Orbis, the flying eye hospital, in Yugoslavia, India and Cuba. Dr. Salz was appointed as the Principal Investigator for four VISX Excimer Laser FDA studies, three Autonomous Technology LADARVision FDA studies, and three Alcon FDA studies at Cedars-Sinai Medical Center in Los Angeles. As a highly respected international lecturer and educator, he has been an invited lecturer and instructor to over 200 eye meetings nationally and internationally. Dr. Salz received his medical degree from Duke University and completed his internship and ophthalmology residency at the University of Southern California (USC) L.A. County Medical Center where he continues to volunteer as Clinical Professor of Ophthalmology..